Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat
Authors:
- Weike BaoWBWeike Bao
- Lucy J HoltLHLucy J Holt
- Rob D PrinceRPRob D Prince
- Gavin X JonesGJGavin X Jones
- Karpagam AravindhanKAKarpagam Aravindhan
- Mathew SzapacsMSMathew Szapacs
- April M BarbourABApril M Barbour
- Larry J JolivetteLJLarry J Jolivette
- John J LeporeJLJohn J Lepore
- Robert N WilletteRWRobert N Willette
- Elena DeAngelisEDElena DeAngelis
- Beat M JuckerBJBeat M Jucker
Open Access
- 1 January 2013
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 12 (1) , 148
Abstract
Glucagon-like peptide-1 (GLP-1) and its mimetics reduce infarct size in the setting of acute myocardial ischemia/reperfusion (I/R) injury. However, the short serum half-life of GLP-1 and its mimetics may limit their therapeutic use in acute myocardial ischemia. Domain antibodies to serum albumin (AlbudAbs) have been developed to extend the serum half-life of short lived therapeutic proteins, peptides and small molecules. In this study, we compared the effect of a long acting GLP-1 agonist, DPP-IV resistant GLP-1 (7–36, A8G) fused to an AlbudAb (GAlbudAb), with the effect of the GLP-1 mimetic, exendin-4 (short half-life GLP-1 agonist) on infarct size following acute myocardial I/R injury.Keywords
This publication has 43 references indexed in Scilit:
- Glucagon-like peptide-1 preserves coronary microvascular endothelial function after cardiac arrest and resuscitation: potential antioxidant effectsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2013
- Glucagon-like Peptide-1 (GLP-1), Immediately Prior to Reperfusion, Decreases Neutrophil Activation and Reduces Myocardial Infarct Size in RodentsHormone and Metabolic Research, 2011
- Emerging cardiovascular actions of the incretin hormone glucagon‐like peptide‐1: potential therapeutic benefits beyond glycaemic control?British Journal of Pharmacology, 2009
- New treatments in type 2 diabetes: a focus on the incretin‐based therapiesClinical Endocrinology, 2009
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent PathwaysCirculation, 2008
- Biology of Incretins: GLP-1 and GIPGastroenterology, 2007
- Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat HeartsThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion InjuryDiabetes, 2005
- Glucagon Like Peptide-1 is Protective Against Myocardial Ischemia/Reperfusion Injury when Given Either as a Preconditioning Mimetic or at Reperfusion in an Isolated Rat Heart ModelCardiovascular Drugs and Therapy, 2005
- Tissue Specific Expression of Different Human ReceptorTypes for Pituitary Adenylate Cyclase Activating Polypeptideand Vasoactive Intestinal Polypeptide: Implications fortheir Role in Human PhysiologyJournal of Neuroendocrinology, 1996